SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+4.69%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$864M
AUM Growth
+$864M
(+2.8%)
Cap. Flow
-$12.3M
Cap. Flow
% of AUM
-1.43%
Top 10 Holdings %
Top 10 Hldgs %
48.36%
Holding
121
New
34
Increased
19
Reduced
27
Closed
25
Top Buys
| 1 |
Generac Holdings
GNRC
|
$13M |
| 2 |
Johnson & Johnson
JNJ
|
$11.9M |
| 3 |
BioXcel Therapeutics
BTAI
|
$11.7M |
| 4 |
Eli Lilly
LLY
|
$9.77M |
| 5 |
Meta Platforms (Facebook)
META
|
$9.17M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$41.2M |
| 2 |
Novo Nordisk
NVO
|
$26.2M |
| 3 |
Fiverr
FVRR
|
$15.2M |
| 4 |
Nice
NICE
|
$15.2M |
| 5 |
Q32 Bio
QTTB
|
$10M |
Sector Composition
| 1 | Healthcare | 83.14% |
| 2 | Technology | 6.68% |
| 3 | Consumer Discretionary | 3.03% |
| 4 | Industrials | 2.58% |
| 5 | Communication Services | 1.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Rocket Pharmaceuticals
RCKT
$354M
| $5.21M | 0.51% | 228,016 -112,000 | -33% | -$2.56M |
|
52
Larimar Therapeutics
LRMR
$310M
| $5.19M | 0.51% | 342,064 -54,723 | -14% | -$830K |
|
53
Kymera Therapeutics
KYMR
$2.95B
| $5.17M | 0.51% | +160,000 | New | +$5.17M |
|
|
INZY
54
DELISTED
Inozyme Pharma
INZY
| $5.16M | 0.51% | +196,411 | New | +$5.16M |
|
55
Ascendis Pharma
ASND
$11.8B
| $5.03M | 0.49% | 32,599 -1,774 | -5% | -$274K |
|
56
uniQure
QURE
$896M
| $4.64M | 0.46% | 126,000 +16,000 | +15% | +$589K |
|
57
Nautilus Biotechnolgy
NAUT
$85.9M
| $4.29M | 0.42% | +400,000 | New | +$4.29M |
|
|
GRTX
58
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $4.24M | 0.42% | 469,245 | – | – |
|
|
TECX
59
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $4.24M | 0.42% | +325,500 | New | +$4.24M |
|
60
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $3.98M | 0.39% | +259,990 | New | +$3.98M |
|
61
Zymeworks
ZYME
$1.12B
| $3.73M | 0.37% | 80,000 -36,310 | -31% | -$1.69M |
|
|
DRNA
62
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $3.6M | 0.35% | +199,980 | New | +$3.6M |
|
63
Passage Bio
PASG
$22.7M
| $3.49M | 0.34% | 266,037 -78,402 | -23% | -$1.03M |
|
64
Perrigo
PRGO
$3.27B
| $3.29M | 0.32% | 71,559 +21,559 | +43% | +$990K |
|
65
Altimmune
ALT
$338M
| $3.21M | 0.32% | +243,000 | New | +$3.21M |
|
66
Arvinas
ARVN
$568M
| $3.19M | 0.31% | +135,000 | New | +$3.19M |
|
|
CNCE
67
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $3.04M | 0.3% | 310,000 -390,710 | -56% | -$3.84M |
|
68
KalVista Pharmaceuticals
KALV
$678M
| $3.02M | 0.3% | 240,140 | – | – |
|
69
argenx
ARGX
$43.6B
| $2.7M | 0.26% | 10,265 | – | – |
|
70
ADMA Biologics
ADMA
$4.12B
| $2.58M | 0.25% | 1,081,292 -903,657 | -46% | -$2.16M |
|
71
Athira Pharma
ATHA
$15.3M
| $2.07M | 0.2% | +112,000 | New | +$2.07M |
|
|
ORGS
72
DELISTED
Orgenesis Inc. Common Stock
ORGS
| $2.01M | 0.2% | 398,803 -266,964 | -40% | -$1.35M |
|
|
ALPN
73
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $1.74M | 0.17% | +198,260 | New | +$1.74M |
|
74
ESSA Pharma
EPIX
$11.4M
| $1.73M | 0.17% | +250,000 | New | +$1.73M |
|
75
Leap Therapeutics
LPTX
$12M
| $1.58M | 0.16% | 800,000 -80,000 | -9% | -$158K |
|